IPP Bureau

Polyplastics announces commercial availability of DURACON POM PM Series for medical industry
Polyplastics announces commercial availability of DURACON POM PM Series for medical industry

By IPP Bureau - June 23, 2023

The company will supply materials to all global regions including Asia such as China, India, Europe, and the U.S.

Lupin receives USFDA approval for Tiotropium Dry Powder Inhaler
Lupin receives USFDA approval for Tiotropium Dry Powder Inhaler

By IPP Bureau - June 22, 2023

This product will be manufactured at Lupin's Pithampur facility in India

Mandaviya reviews preparedness to the ongoing heat wave in 7 affected states
Mandaviya reviews preparedness to the ongoing heat wave in 7 affected states

By IPP Bureau - June 22, 2023

Effective disaster response and management is a collaborative work

Max Healthcare and IIT Bombay ink MoU for innovation in the healthcare industry
Max Healthcare and IIT Bombay ink MoU for innovation in the healthcare industry

By IPP Bureau - June 22, 2023

Quantiphi join hands with Pharmarack and Snowflake to drive AI based innovation
Quantiphi join hands with Pharmarack and Snowflake to drive AI based innovation

By IPP Bureau - June 21, 2023

This partnership will revolutionize Pharmarack's digital infrastructure with Snowflake's single, integrated platform to facilitate advanced analytic

Verix acquires start-up.ai
Verix acquires start-up.ai

By IPP Bureau - June 21, 2023

The start-up.ai team will be integrated into Verix, boosting its innovative Life Science AI capabilities

DGCI grants Emergency Use Authorisation to Gennova mRNA Covid booster vaccine
DGCI grants Emergency Use Authorisation to Gennova mRNA Covid booster vaccine

By IPP Bureau - June 21, 2023

The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield

Mandaviya inaugurates G20 co-branded event of PMNCH, Geneva on health
Mandaviya inaugurates G20 co-branded event of PMNCH, Geneva on health

By IPP Bureau - June 21, 2023

Dignitaries and delegates commend India’s leadership in Global South during G20 India Presidency

Lupin signs MoU with Govt. of Maharashtra to combat rising prevalence of cardiovascular diseases
Lupin signs MoU with Govt. of Maharashtra to combat rising prevalence of cardiovascular diseases

By IPP Bureau - June 21, 2023

The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence

Croda opens technical centre in Hyderabad
Croda opens technical centre in Hyderabad

By IPP Bureau - June 21, 2023

The investment is part of Croda’s continuing commitment to develop high performance pharmaceutical ingredients and technologies for life sciences.

Nouryon launches new high-efficiency spherical silica for peptide-based pharmaceuticals
Nouryon launches new high-efficiency spherical silica for peptide-based pharmaceuticals

By IPP Bureau - June 21, 2023

This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments

Biostar Pharma receives FDA approval Utidelone Injectable Phase 2/3 clinical trial for cell lung cancer
Biostar Pharma receives FDA approval Utidelone Injectable Phase 2/3 clinical trial for cell lung cancer

By IPP Bureau - June 20, 2023

This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable

Zydus receives final approval from the USFDA for Minocycline Hydrochloride ER Tablets
Zydus receives final approval from the USFDA for Minocycline Hydrochloride ER Tablets

By IPP Bureau - June 20, 2023

The group now has 372 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.

Alkem Laboratories launches awareness initiative
Alkem Laboratories launches awareness initiative "Stop Sneeze to Wheeze"

By IPP Bureau - June 19, 2023

Approximately 60 to 78% of individuals diagnosed with Asthma also have concurrent Allergic Rhinitis

USFDA approves Roche’s Columvi for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma
USFDA approves Roche’s Columvi for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma

By IPP Bureau - June 19, 2023

Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma

Latest Stories

Interviews

Packaging